Valtra

Valtra

valaciclovir

Manufacturer:

Jeil Pharm

Distributor:

Yu Chun
/
SB Pharma
Concise Prescribing Info
Contents
Valaciclovir HCl sesquihydrate
Indications/Uses
Herpes zoster (shingles) & ophth zoster in immunocompetent adults, herpes zoster in adult patients w/ mild or moderate immunosuppression. Treatment & suppression of herpes simplex virus (HSV) infections of the skin & mucous membranes in adult & adolescent, including treatment of 1st-episode of & recurrences of genital herpes; suppression of recurrent genital herpes. Treatment & suppression of recurrent ocular HSV infections. Prophylaxis of CMV infection & disease following solid organ transplantation in adults & adolescents.
Dosage/Direction for Use
Varicella zoster virus infections - herpes zoster & ophth zoster Immunocompetent adult 1,000 mg tds for 7 days. Immunocompromised adult 1,000 mg tds for at least 7 days & for 2 days following crusting of lesions. CrCl ≥50 mL/min 1,000 mg tds; 30-49 mL/min 1,000 bd; 10-29 mL/min 1,000 mg once daily; 10 mL/min 500 mg once daily. Herpes simplex virus (HSV) Immunocompetent adult & adolescent ≥12 yr (CrCl ≥30 mL/min) 500 mg bd; CrCl <30 mL/min 500 mg once daily. Immunocompromised adult (CrCl ≥30 mL/min) 1,000 mg bd for at least 5 days; CrCl <30 mL/min 1,000 mg once daily. Herpes labialis Immunocompetent adult & adolescent (CrCl ≥50 mL/min) 2,000 mg bd for 1 day. Take 2nd dose about 12 hr (no sooner than 6 hr) after the 1st dose; CrCl 30-49 mL/min 1,000 mg bd in 1 day; 10-29 mL/min 500 mg bd in 1 day; <10 mL/min 500 mg single dose. Suppression of recurrences of HSV infections Immunocompetent adult & adolescent ≥12 yr (CrCl ≥30 mL/min) 500 mg once daily. For immunocompetent subjects w/ a history of ≥10 recurrences/yr, better results may be obtained w/ 250 mg bd. CrCl <30 mL/min 250 mg once daily. Immunocompromised adult ≥30 mL/min 500 mg bd; CrCl <30 mL/min 500 mg once daily. Prophylaxis of cytomegalovirus infection & disease Adult & adolescent ≥12 yr (CrCl ≥75 mL/min) 2,000 mg qds, to be initiated as early as possible post-transplant; CrCl 50 to <75 mL/min 1,500 mg qds; 25 to <50 mL/min 1,500 mg tds; 10 to <25 mL/min 1,500 mg bd; <10 mL/min or on dialysis 1,500 mg once daily. Patients on intermittent haemodialysis Give the dose after dialysis on dialysis days. Childn The efficacy in childn <12 yr has not been evaluated. Elderly Adjust dose accordingly. Hepatic impairment Dose modification is not required.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Ensure adequate fluid intake in patients at risk of dehydration. Consider giving IV antiviral therapy when response to oral therapy is considered insufficient. Risk of transmission of genital herpes is still possible. Use valaciclovir only when safety concerns preclude the use of valganciclovir or ganciclovir. Hepatic impairment & liver transplantation. Renal impairment. Pregnancy & lactation. Elderly.
Adverse Reactions
Headache; nausea; dizziness; vomiting, diarrhoea; rashes including photosensitivity, pruritus.
MIMS Class
Antivirals
ATC Classification
J05AB11 - valaciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Valtra tab 500 mg
Packing/Price
7 × 6's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in